Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02468674 · ClinicalTrials.gov registry record · Phase 2
A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT02468674 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 160 participants.
The verdict
NCT02468674, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
This extension study was a 24-week off-drug follow-up of the core CBYM338E2202 (NCT ) study and the main objective was to determine the long-term durability of bimagrumab (BYM338) effect after a 6-month treatment period.
Interventions
- DRUG Placebo
- DRUG bimagrumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2015-07-22 |
| Est. Completion | 2018-12-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02468674
The ClinicalTrials.gov registry entry for NCT02468674 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02468674 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02468674 about?
NCT02468674 is a clinical study titled "A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study". This extension study was a 24-week off-drug follow-up of the core CBYM338E2202 (NCT ) study and the main objective was to determine the long-term durability of bimagrumab (BYM338) effect after a 6-month treatment period.
What is the current status of trial NCT02468674?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2015-07-22. Estimated completion is 2018-12-03.
What interventions are being tested in trial NCT02468674?
The interventions under investigation include: Placebo (DRUG), bimagrumab (DRUG).
Who is sponsoring clinical trial NCT02468674?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.